Browsing Tag
mRNA-4157
3 posts
Moderna (MRNA) and Merck (MRK) cancer vaccine sustains benefit at five years, but investors stay cautious
Moderna and Merck's mRNA cancer vaccine sustained a 49% reduction in melanoma recurrence at five years, but MRNA fell as investors weigh near-term pressures.
Five-year data boosts Moderna and Merck’s neoantigen vaccine strategy in adjuvant melanoma
Moderna and Merck reveal 5-year data showing 49% reduction in melanoma recurrence with their mRNA-4157 and KEYTRUDA combo. Read more on what’s next.
Moderna, Merck announce promising results for mRNA-4157 and Keytruda in melanoma
Moderna, Inc. (NASDAQ: MRNA) and Merck (NYSE: MRK), also known as MSD outside the United States and Canada,…